4,4'-(1,5-戊二氧基)二苯胺 | 2391-56-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4,4'-(1,5-戊二氧基)二苯胺
• 中文别名: 1,5-双(4-氨苯氧基)戊烷；4,4’-(1,5-戊二氧基)二苯胺
• 英文名称: 1,5-bis(4-aminophenoxy)pentane
• 英文别名: 4,4'-pentanediyldioxy-di-aniline；1,5-Bis-(4-amino-phenoxy)-pentan；4,4'-Pentandiyldioxy-di-anilin；1,5-bis(4-aminophenoxy)-pentane；4-[5-(4-aminophenoxy)pentoxy]aniline
• CAS: 2391-56-2
• 化学式: C₁₇H₂₂N₂O₂
• 分子量: 286.374
• InChiKey: SLHXQWDUYXSTPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  70.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 安全说明：
  S36/37/39,S45
• 危险类别码：
  R20/21/22
• 海关编码：
  2922299090
• 储存条件：
  存储条件：室温、避光、惰性气体环境中

反应信息

• 作为反应物：
  描述：

  4,4'-(1,5-戊二氧基)二苯胺 在 过氧乙酸 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 生成
  参考文献：
  名称：

  Biological properties of amidinium sulfinic and sulfonic acid derivatives: inhibition of glycolytic enzymes of Trypanosoma brucei and protective effect on cell growth

  摘要：

  The activity of the title compounds has been investigated on two biological targets: cultures of trypanosome and glycolytic enzymes inhibition of the parasite, and on retinal epithelium cells. In both cases, these compounds exhibit a significant activity, in some cases more selective than this for the drug suramin, with a lower toxicity. The effect of these compounds, which exist as neutral and zwitterionic forms in the case of sulfinic, only as zwitterionic in the case of sulfonic derivatives can be understood via their action on clusters of positive charges which are present at the surface of the proteins involved in the processes: glycolytic enzymes of the trypanosome in the first part, basic fibroblast growth factor in the second.

  DOI：

  10.1016/0223-5234(92)90114-g
• 作为产物：
  描述：

  4-nitrophenol sodium salt 在 palladium on activated charcoal 氢气 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 4,4'-(1,5-戊二氧基)二苯胺
  参考文献：
  名称：

  Novel bis[1,6-dihydro-6,6-dimethyl-1,3,5-triazine-2,4-diamines] as antitrypanosomal agents

  摘要：

  A series of novel 1,1'-(4,1-phenylene)bis [1,6-dihydro-6,6-dimethyl-1,3,5-triazine-2,4-diamines] was prepared and evaluated for activity against Trypanosoma rhodesiense in mice. The importance of the bis structure and the nature of the spacer between the two phenyl rings for optimal activity have been revealed. The potent parenteral activity of several analogues within this series as well as preliminary indication of oral activity lends encouragement to further development of this structural class.

  DOI：

  10.1021/jm00149a032

文献信息

• Integrase inhibitors
  申请人：Cai R. Zhenhong

  公开号：US20080058315A1

  公开（公告）日：2008-03-06

  Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

  三环化合物，其受保护的中间体，以及用于抑制HIV整合酶的方法被披露。
• Integrase inhibitor compounds
  申请人：Cai R. Zhenhong

  公开号：US20070072831A1

  公开（公告）日：2007-03-29

  Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

  三环化合物、其受保护的中间体以及用于抑制HIV整合酶的方法被披露。
• Chiral liquid crystal tetramers
  作者：Toby Donaldson、Peter A. Henderson、Marie France Achard、Corrie T. Imrie

  DOI：10.1039/c1jm10992h

  日期：——

  The synthesis and characterisation of two new series of liquid crystal tetramers in which four mesogenic groups are linked via three alkyl spacers is reported. In each series the length of the outer two spacers, n, is varied between 3, 4, 5, 7, 10 and 11 methylene units while the central spacer length, m, is either 5 or 6 methylene units. The outer two mesogenic groups are cholesteryl-based, Chol, while the inner two are Schiff's bases, SB. The tetramers are referred to by the acronym Chol-n-SB-m-SB-n-Chol. All twelve tetramers exhibit an enantiotropic chiral nematic phase. The chiral nematic-isotropic transition temperatures and associated entropy changes depend critically on the combination of spacers in the tetramer and this is interpreted in terms of average molecular shapes. The tetramers with m = 5 and n = 5, 7, and m = 6 and n = 3, 4, 5, 7, show a monolayer chiral smectic C* phase, the driving force for which may be the mismatch in the cross-sectional areas of the differing mesogenic groups. The tetramers with m=6 and n = 10, 11 show a quadruply intercalated smectic A phase characterised by a smectic periodicity to estimated molecular length ratio of just 0.23. The driving force for the formation of this phase is thought to be specific electrostatic interactions between the unlike mesogenic units while the formation of the phase is strongly dependent on the length and parity of the spacers due to packing constraints. On cooling, a new phase transition is seen, possibly driven by conformational changes in the outer flexible spacers, for both these tetramers from the intercalated smectic A phase to an intercalated alternating chiral smectic C* phase in which the layers consist of either the mixed mesogenic groups or solely the cholesteryl-based moieties.

  报道了两种新型液晶四聚体的合成和表征，其中四个介晶基团通过三个烷基间隔基连接。在每一系列中，外部两个间隔基的长度n在3、4、5、7、10和11个亚甲基单元之间变化，而中央间隔基的长度m为5或6个亚甲基单元。外部的两个介晶基团是胆固醇基的，记为Chol，而内部的两个是席夫碱，记为SB。这些四聚体用缩写Chol-n-SB-m-SB-n-Chol表示。所有十二个四聚体都表现出手性向列相的性质。手性向列相-各向同性相的转变温度及其相关的熵变化关键取决于四聚体中间隔基的组合，这可以通过平均分子形状来解释。具有m=5和n=5、7以及m=6和n=3、4、5、7的四聚体显示出单层手性近晶C*相，其形成的驱动力可能是不同介晶基团横截面积的不匹配。具有m=6和n=10、11的四聚体显示出四重交错排列的近晶A相，其特征是近晶层周期与估计分子长度之比仅为0.23。该相形成的驱动力被认为是不同介晶单元之间的特定静电相互作用，而相的形成强烈依赖于间隔基的长度和奇偶性，这是由于堆积限制。在冷却过程中，对于这两个四聚体，从交错排列的近晶A相到交错排列的交替手性近晶C*相，出现了一个新的相变，这种相变可能是由外部柔性间隔基的构象变化驱动的，其中层由混合介晶基团或仅由胆固醇基部分组成。
• MODULATORS OF TOLL-LIKE RECEPTORS
  申请人：Desai Manoj C.

  公开号：US20100143301A1

  公开（公告）日：2010-06-10

  Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

  提供了公式II的TLR调节剂：其药用盐，含有这类化合物的组合物，以及包括给予这类化合物的治疗方法。
• [EN] SALTS OF HIV INHIBITOR COMPOUNDS<br/>[FR] SELS DE COMPOSÉS INHIBITEURS DU VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2010005986A1

  公开（公告）日：2010-01-14

  The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts.

  这项发明涉及抗病毒化合物的盐、含有这种盐的组合物，以及包括给予这种盐的治疗方法，还涉及用于制备这种盐的过程和中间体。